Susceptibility of Gram-negative bacteria to isepamicin: a systematic review

Expert Review of Anti-infective Therapy
Matthew E FalagasPetros I Rafailidis

Abstract

We sought to review the potential role of isepamicin against infections with contemporary Gram-negative bacteria. We searched PubMed and Scopus databases to identify relevant microbiological and clinical studies published between 2000 and 2010, and we retrieved 11 and three studies, respectively. A total of 4901 isolates were examined in the in vitro studies. Isepamicin had higher in vitro activity compared with amikacin in four studies, was as active as amikacin in six studies and in the remaining study both were inactive. Regarding specifically the studies that included multidrug-resistant bacteria, isepamicin appeared superior to amikacin in two studies, as active as amikacin in one study and both did not exhibit activity in one study. In the clinical studies, isepamicin was as active as amikacin for the treatment of 55 children with urinary tract infections. In conclusion, isepamicin might be active in vitro against Gram-negative bacteria with resistance to amikacin and other aminoglycosides.

References

Oct 1, 1980·Antimicrobial Agents and Chemotherapy·A L BarryE H Gerlach
Jan 1, 1997·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·G H MillerK J Shaw
Apr 2, 1999·Antimicrobial Agents and Chemotherapy·M P Mingeot-LeclercqP M Tulkens
Mar 16, 2000·International Journal of Antimicrobial Agents·D A KafetzisC Bartsokas
Apr 5, 2000·Clinical Pharmacokinetics·M TodO Petitjean
Oct 27, 2001·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·U OverUNKNOWN Aminoglycoside Resistance Study Group
Nov 3, 2001·International Journal of Antimicrobial Agents·H C MaltezouD A Kafetzis
Feb 2, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David M Livermore
Feb 4, 2003·The Journal of Antimicrobial Chemotherapy·J Van Eldere
May 25, 2004·Antimicrobial Agents and Chemotherapy·Yohei DoiYoshichika Arakawa
Jan 28, 2005·Antimicrobial Agents and Chemotherapy·Keith Poole
Jul 30, 2005·BMJ : British Medical Journal·Sean C Sweetman
Sep 16, 2005·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Zulal Asci ToramanAhmet Kizirgil
Dec 20, 2005·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Nai-Cheng ChengCheng-Yi Liu
Jan 13, 2006·Diagnostic Microbiology and Infectious Disease·Lii-Tzu WuWen-Liang Yu
Jun 8, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Yohei Doi, Yoshichika Arakawa
Jun 15, 2007·Antimicrobial Agents and Chemotherapy·Azita LeavittYehuda Carmeli
Sep 1, 2007·Current Opinion in Critical Care·Matthew E Falagas, Petros Kopterides
Jan 25, 2008·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·M E FalagasE A Papafrangas
Feb 26, 2008·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Kazuyoshi ShigeharaMasayoshi Shimamura
May 1, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Matthew E Falagas, Drosos E Karageorgopoulos
Jun 14, 2008·Expert Opinion on Investigational Drugs·Matthew E Falagas, Petros I Rafailidis
Nov 4, 2008·International Journal of Antimicrobial Agents·Emanuele Durante-MangoniMatthew E Falagas
Mar 25, 2009·Antimicrobial Agents and Chemotherapy·Alessandra Carattoli
Aug 22, 2009·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·A MichalopoulosM E Falagas
Jan 1, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Maria SouliHelen Giamarellou
Feb 11, 2010·Antimicrobial Agents and Chemotherapy·Marta TothSergei B Vakulenko
Mar 3, 2010·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Mariana CastanheiraRonald N Jones
Mar 31, 2010·Antimicrobial Agents and Chemotherapy·Azita LeavittShiri Navon-Venezia
Oct 20, 2010·Antimicrobial Agents and Chemotherapy·Katarzyna ZacharczukRafal Gierczynski
Nov 17, 2010·The Journal of Antimicrobial Chemotherapy·D M LivermoreN Woodford
Jan 20, 2011·Antimicrobial Agents and Chemotherapy·Laurent PoirelPatrice Nordmann

❮ Previous
Next ❯

Citations

Jul 4, 2012·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·G SamonisM E Falagas
Jun 12, 2013·Expert Opinion on Pharmacotherapy·Panagiotis Poulikakos, Matthew E Falagas

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.